TCGA-D8-A27K-01A-11R-A16F-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 49
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.380
- TGF_BETA_SIGNALING+0.360
- UV_RESPONSE_DN+0.350
- NOTCH_SIGNALING+0.320
- HEDGEHOG_SIGNALING+0.310
- PROTEIN_SECRETION+0.240
- APICAL_SURFACE+0.170
- MITOTIC_SPINDLE+0.120
- IL6_JAK_STAT3_SIGNALING+0.110
- ALLOGRAFT_REJECTION+0.100
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- E2F_TARGETS-0.510
- OXIDATIVE_PHOSPHORYLATION-0.460
- MTORC1_SIGNALING-0.420
- MYC_TARGETS_V1-0.410
- PANCREAS_BETA_CELLS-0.410
- DNA_REPAIR-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- UV_RESPONSE_UP-0.370
- G2M_CHECKPOINT-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A145-01A-11R-A115-07 | — | A | 0.857 |
| 2 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.842 |
| 3 | TCGA-E2-A15I-01A-21R-A137-07 | — | B | 0.833 |
| 4 | TCGA-AC-A2FK-01A-12R-A180-07 | — | A | 0.826 |
| 5 | SRR8613708 | — | A | 0.821 |
| 6 | 20030061.LumA | — | A | 0.818 |
| 7 | TCGA-AC-A3QQ-01B-06R-A22O-07 | — | D | 0.816 |
| 8 | TCGA-A7-A26E-01B-06R-A277-07 | — | D | 0.815 |
| 9 | TCGA-D8-A1XO-01A-11R-A14M-07 | — | B | 0.814 |
| 10 | AUR-AFE4-TTP1-A-1-0-R-A741-41 | — | D | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |